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Background
● Even though catheter ablation of ventricular tachycardia (VT) has become a popular option to 
treat patients with nonischemic cardiomyopathy, there are few to none randomized studies on 
VT ablation on this population.
● Three options to treat VT: antiarrhythmic drugs (AADs), implantable cardioverter-defibrillator 
(ICD), and catheter ablation (CA)
○ CA is the most common treatment for VT in nonischemic cardiomyopathy patients.
● CA for VT in nonischemic cardiomyopathy (NICM) patients is reported to be less favorable 
than with patients with ischemic cardiomyopathy (ICM).
○ This study uses a large group of patients globally to evaluate outcomes of NICM who 
underwent a VT catheter ablation through the observation of specific etiologies and 
adjusting outcomes for known comorbidities.
● International Collaborative Study across 12 centers with data from 2,075 patients with structural 
heart disease who were referred for catheter ablation of VT 
● 780 NICM patients of the 2,075 structural heart disease patients
○ Mean age: 57 ± 14 years, 18% women, left ventricular ejection fraction 37 ± 13%
● 6 most common NICM etiologies for further data collection:
○ Myocarditis
○ Arrhythmogenic right ventricular cardiomyopathy (ARVC)






● 2,075 patients with structural heart disease with a catheter ablation performed between 
2002-2014 → 780 patients with NICM and an identified etiology
● Largest confounding variables were taken into account with adjusted etiology data for VT 
recurrences, death, and cardiac transplantation
○ Age, NYHA functional class, LVEF, ablation center, prior VT ablation, etc. 
● One-year freedom from VT was 69%, and freedom from VT, heart transplantation, and death 
was 62%.
● Unadjusted Competing Risk Analysis Conclusion: VT ablation in ARVC showed greater VT-free 
survival than DICM; 82% for ARVC did not express VT factors in follow-ups
○ Valvular cardiomyopathy had the poorest survival with 42% of patients showing VT 
recurring factors.
● Adjusted Comorbidities: myocarditis, ARVC, and DICM had similar outcomes and the most 
positive results; hypertrophic cardiomyopathy, valvular cardiomyopathy, and sarcoidosis had the 




● Largest study to analyze VT ablation outcomes in these specific NICM etymologies: valvular 
heart disease, myocarditis, and HCM
● One of the initial studies to explore the effects of certain etiologies on catheter ablation for VT 
in patients with NICM
● Global study across specialized VT ablation centers also allowed this study to have a large 
number of patients for participation.
● Main Conclusion: Etiology of NICM is a significant predictor of VT recurrence, death, and 
cardiac transplantation. 
● Future outlooks: translational studies and specific models of NICM to better understand specific 
etiologies and the characterization of the substrates
● What are some advantages of performing an international collaborative 
study?
○ What are some disadvantages?
● What might be some study limitations for this specific study?
○ Discussion of confounders
Discussion among members was led to critically think about these questions in relation to this study, as well 
as how other medical studies in various fields might be impacted by performing a global study, rather than a 
localized or even a national study. Although this study took into perspective the possibility of the presence of 
confounders, it is not logistically possible to review every additional factor that might affect the results, 
especially with an international study. However, as this is one of the largest studies to analyze VT ablation in 
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